A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)

Date Added
April 15th, 2024
PRO Number
Pro00135209
Researcher
Patrick Flume

List of Studies


Keywords
Bronchiectasis, Lung, Pulmonary
Summary

This trial is for patients with bronchiectasis who completed the Boehringer Ingelheim 1397-0012 Airleaf parent study. This is a continuation of the Airleaf study and is meant to assess the long-term safety, effectiveness, and tolerability of the study drug (BI 1291583). Approximately 220 patients will be enrolled into the study and will be randomized into either 1 milligram, 2.5 milligram, or 5 milligram study drug or placebo. Patients will be treated for approximately 1 year, while study staff monitor the number of patient pulmonary exacerbations.

Institution
MUSC
Recruitment Contact
Zerlinna Teague
8437920965
recruitment@musc.edu